Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention: Munich, Germany Wednesday, April 9, 2025, 13:00 Hrs [IST] Ethris, a clinical- ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...

Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...

Nipah virus, a highly lethal pathogen belonging to the Paramyxovirus family, has caused multiple outbreaks in South and ...

Gennova Biopharmaceuticals, in partnership with CEPI, will advance the development of a self-amplifying mRNA vaccine against ...

The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug ...

The federal government is allocating an additional $1 billion to combat the avian bird flu leading to culling and high egg ...

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to ...